ID   ZJU-1127
AC   CVCL_XC11
DR   cancercelllines; CVCL_XC11
DR   CCRID; 4201PAT-CCTCC01126
DR   Wikidata; Q98136536
RX   Patent=CN108034636B;
RX   PubMed=30140169;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017172.
CC   Population: Chinese.
CC   Doubling time: 18.8 hours (Patent=CN108034636B).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Asn (c.376T>A); ClinVar=VCV000428871; Zygosity=Unspecified (PubMed=30140169).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_XC10 ! ZJU-0725
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 05-10-23; Version: 8
//
RX   Patent=CN108034636B;
RA   Sun J.-H., Yang X.-M., Zhou F., Zhang Y.-H.;
RT   "Human breast cancer cell lines and application.";
RL   Patent number CN108034636B, 11-Jan-2019.
//
RX   PubMed=30140169; DOI=10.1186/s12935-018-0617-9;
RA   Zhou F., Zhang Y.-H., Xu X.-F., Luo J.-F., Yang F., Wang L.-B.,
RA   Xie S.-D., Sun J.-H., Yang X.-M.;
RT   "Establishment and characterization of three stable
RT   basal/HER2-positive breast cancer cell lines derived from Chinese
RT   breast carcinoma with identical missense mutations in the DNA-binding
RT   domain of TP53.";
RL   Cancer Cell Int. 18:118.1-118.15(2018).
//